Recombinant Xenopus tropicalis Serine/threonine-protein kinase PLK1 (plk1), partial
Description
Overview of Recombinant Xenopus tropicalis PLK1
Recombinant PLK1 refers to a truncated or partial form of the native Polo-like kinase 1 enzyme, produced in heterologous expression systems (e.g., E. coli or insect cells). This kinase is critical for mitotic progression, DNA replication, and checkpoint adaptation in vertebrates . The "partial" designation indicates that only specific functional domains (e.g., kinase or polo-box domains) are expressed, enabling targeted studies of kinase activity or protein interactions .
Key Domains
-
Phosphorylation Sites:
Experimental Findings from Xenopus Studies
-
Mechanistic Insight:
Plk1 promotes origin firing by phosphorylating Rif1 at S2058, disrupting its interaction with PP1 and relieving replication suppression at late-firing origins .
Table: Key Uses of Recombinant PLK1 in Studies
Role in Checkpoint Adaptation
-
Plk1 depletion increases Chk1 phosphorylation (activation) and reduces Cdk2 activity, delaying S-phase progression .
-
Recombinant Plk1 rescues replication defects in depleted extracts, confirming its direct role in origin firing .
Interaction with XErp1
-
Plk1 phosphorylates XErp1 (Emi1-related protein) to regulate APC/C activity during mitosis .
-
Dominant-negative Plk1 constructs stabilize XErp1, preventing premature APC/C activation and mitotic exit .
Limitations and Open Questions
-
Partial Construct Constraints: Truncated PLK1 lacks full regulatory domains (e.g., polo-box), limiting studies on subcellular localization .
-
Evolutionary Conservation: While Xenopus PLK1 parallels human PLK1 functionally, post-translational modifications may differ .
Future Directions
-
High-Resolution Structural Studies: Cryo-EM of PLK1-Rif1/PP1 complexes to define phosphorylation-driven conformational changes.
-
Therapeutic Targeting: Screen inhibitors against recombinant PLK1 for cancer therapy applications.
